Promising data on the use of antibody-based regimens in both newly diagnosed and relapsed/refractory multiple myeloma were presented at the 62nd AS......READ MORE
Important new research on cellular and immune-based therapies for relapsed/refractory multiple myeloma was presented at the 62nd ASH Annual Meeting......READ MORE
Patients with multiple myeloma currently have more treatment options than ever before; however, there is still no cure. Researchers at the 62nd ASH......READ MORE
At the 62nd ASH Annual Meeting and Exposition, emerging data were presented relevant to the treatment of frail and/or older patients with multiple ......READ MORE
Patients with multiple myeloma may develop immunoglobulin light chain (AL) amyloidosis during the course of their disease. Several abstracts presen......READ MORE
At the 62nd ASH Annual Meeting and Exposition, important new research was presented on cellular and immune-based therapies for relapsed/refractory ......READ MORE
